Chinese innovative drug stocks slide; Nearshore Protein falls over 12%

The pullback is notable less for any single name than for its breadth: a double-digit decline in Nearshore Protein paired with uniform 5%-plus drops across Reme, North China, Wanbang, Baihua and Tellgen points to a sector-wide de-risking rather than an idiosyncratic story. For a concept sector that trades heavily on sentiment around innovative pipelines, that kind of synchronized move suggests positioning is being unwound broadly. Whether the selling stays confined to the concept cohort or spills into the wider healthcare complex is the open question worth tracking.